Yuanyao Dou
Overview
Explore the profile of Yuanyao Dou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dou Y, Liu Y, Han R, Zheng J, Wang L, Hu C, et al.
Adv Healthc Mater
. 2025 Feb;
:e2404087.
PMID: 39967371
Acquired resistance to osimertinib (Osi) remains a major obstacle in the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). AXL elevation is a known key mechanism of Osi-resistance,...
2.
Liu Z, Dou Y, Lu C, Han R, He Y
Biomark Res
. 2025 Jan;
13(1):12.
PMID: 39849606
Neutrophil extracellular traps (NETs) are intricate, web-like formations composed of DNA, histones, and antimicrobial proteins, released by neutrophils. These structures participate in a wide array of physiological and pathological activities,...
3.
Liu Y, Xu L, Dou Y, He Y
Mol Cancer
. 2025 Jan;
24(1):11.
PMID: 39799359
As research progresses, our understanding of the tumor microenvironment (TME) has undergone profound changes. The TME evolves with the developmental stages of cancer and the implementation of therapeutic interventions, transitioning...
4.
Wang Z, Li K, Lu C, Feng M, Lin C, Yin G, et al.
Oncol Res
. 2024 Sep;
32(10):1637-1648.
PMID: 39308524
Background: Metformin has pleiotropic effects beyond glucose reduction, including tumor inhibition and immune regulation. It enhanced the anti-tumor effects of programmed cell death protein 1 (PD-1) inhibitors in serine/threonine kinase...
5.
Dou Y, Zheng J, Kang J, Wang L, Huang D, Liu Y, et al.
iScience
. 2024 Jul;
27(7):110150.
PMID: 39040065
Targeting the stimulator of interferon genes (STING) pathway is a promising strategy to overcome primary resistance to immune checkpoint inhibitors in non-small cell lung cancer with the STK11 mutation. We...
6.
Lu C, Gao Z, Wu D, Zheng J, Hu C, Huang D, et al.
J Immunother Cancer
. 2024 Jun;
12(6).
PMID: 38908857
Background: The dynamic interplay between tyrosine kinase inhibitors (TKIs) and the tumor immune microenvironment (TME) plays a crucial role in the therapeutic trajectory of non-small cell lung cancer (NSCLC). Understanding...
7.
Han R, Lin C, Lu C, Wang Y, Kang J, Hu C, et al.
Cancer Lett
. 2024 Feb;
588:216762.
PMID: 38408602
The third-generation EGFR-TKI osimertinib is widely used in EGFR-mutated positive non-small cell lung cancer (NSCLC) patients, but drug resistance is inevitable. The currently known mechanisms only explain resistance in a...
8.
Zheng J, Dou Y, Huang D, Wang Y, Han R, Hu C, et al.
Jpn J Clin Oncol
. 2023 Sep;
54(1):89-96.
PMID: 37721193
Objective: Numerous scattered case studies continue to demonstrate a strong correlation between acquired KRAS mutations and epidermal growth factor receptor-tyrosine kinase inhibitor resistance in non-small cell lung cancer. However, the...
9.
Zheng J, Wang Y, Hu C, Zhu M, Ii J, Lin C, et al.
Thorac Cancer
. 2022 Oct;
13(22):3162-3173.
PMID: 36193794
Background: Circulating tumor DNA (ctDNA) has made a breakthrough as an early biomarker in operable early-stage cancer patients. However, the function of ctDNA combined with cell-free DNA (cfDNA) as a...
10.
Dou Y, Zhang Y, Lin C, Han R, Wang Y, Wu D, et al.
Front Bioeng Biotechnol
. 2022 Sep;
10:983677.
PMID: 36159657
Multiple component integration to achieve both therapy and diagnosis in a single theranostic nanosystem has aroused great research interest in the medical investigator. This study aimed to construct a novel...